Hikma Pharmaceuticals PLC (LON: HIK)

Market Cap	4.33B
Revenue (ttm)	2.39B
Net Income (ttm)	225.51M
Shares Out	221.75M
EPS (ttm)	1.01
PE Ratio	19.40
Forward PE	10.90
Dividend	0.63 (3.22%)
Ex-Dividend Date	Aug 15, 2024

Volume	801,595
Open	1,932.00
Previous Close	1,935.00
Day's Range	1,918.00 - 1,959.13
52-Week Range	1,750.00 - 2,165.00
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 21, 2025

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various th...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 9,100
• Stock Exchange: London Stock Exchange
• Ticker Symbol: HIK

Financial Performance

In 2023, Hikma Pharmaceuticals's revenue was $2.88 billion, an increase of 14.22% compared to the previous year's $2.52 billion. Earnings were $190.00 million, an increase of 1.06%.

Financial numbers in USD